期刊文献+

自拟抑癌汤联合多西他赛化疗对去势抵抗前列腺癌的疗效观察

Efficacy of the Yiai decoction with docetaxel chemotherapy on castration resistance to prostate cancer
下载PDF
导出
摘要 目的:探讨自拟抑癌汤联合多西他赛化疗对去势抵抗前列腺癌(Castration-Resistant Prostate Cancer,CRPC)的疗效。方法:选取2014年12月-2019年12月收治的CRPC患者36例进行研究,随机数字表法分为对照组与观察组各18例,对照组采用多西他赛化疗,观察组在对照组基础上加自拟抑癌汤,对两组治疗效果、疼痛程度、前列腺特异性抗原(Prostate Specific antigen,PSA)、肿瘤体积进行比较。结果:观察组治疗总有效率明显较对照组高(P<0.05);两组治疗前的视觉模拟评分法(Visual Analogue Scale,VAS)评分、PSA、肿瘤体积无明显差异(P>0.05),观察组治疗后上述指标与对照组比较有明显差异(P<0.05);观察组胃肠道反应、骨髓抑制等不良反应发生率明显低于对照组(P<0.05);治疗前两组卡氏评分(Karnofsky,KPS)无明显差异(P>0.05),观察组治疗后KPS评分均高于对照组,治疗后平均生存时间较对照组长(P<0.05)。结论:自拟抑癌汤联合多西他赛化疗治疗CRPC能提高疗效,改善临床相关指标,也能减少化疗不良反应发生率,值得推广。 Objective:To explore the effect of the Yiai decoction(抑癌汤)with docetaxel chemotherapy on castration resistance to prostate cancer.Methods:36 patients were divided into the control group and the observation group,18 cases in each.The control group was treated by docetaxel chemotherapy.The observation group was given the Yiai decoction more.Results:The total efficiency in the observation group was significantly higher than the control group(P<0.05).VAS,PSA and tumor volume in the observation group were better than those in the control group after treatment(P<0.05).The incidence of gastrointestinal reactions and bone marrow suppression in the observation group was lower than the control group(P<0.05).KPS in the observation group were higher than the control group,and the median survival time after treatment was longer than the control group(P<0.05).Conclusion:The Yiai decoction with docetaxel chemotherapy on castration-resistant prostate cancer was effective,can improve the clinical indicators,and reduce the incidence of chemotherapy toxicity,which is worthy of promotion.
机构地区 中山市中医院
出处 《中医临床研究》 2021年第14期125-127,共3页 Clinical Journal Of Chinese Medicine
关键词 自拟抑癌汤 多西他赛化疗 去势抵抗前列腺癌 The Yiai decoction Docetaxel chemotherapy Castration resistance to prostate cancer
  • 相关文献

参考文献10

二级参考文献121

  • 1姜可伟.规范全球第二大致死率疾病的诊断——《胃癌诊断标准》解读[J].中国卫生标准管理,2010,1(4):26-28. 被引量:77
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 3王米渠,王宇,骆永珍,白华,黄健.“恐伤肾”对小鼠红细胞免疫及免疫器官的影响[J].成都中医药大学学报,1996,19(2):34-35. 被引量:28
  • 4Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin, 2015, 65 (1) :5-29.
  • 5Zong Y, Goldstein AS. Adaptation or selection-mecha- nisms of castration-resistant prostate cancer [J]. Nat Rev Urol, 2013, 10(2) :90-98.
  • 6Pienta KJ, Bradley D. Mechanisms underlying the devel- opment of androgen-independent prostate cancer [J]. Clin Cancer Res, 2006, 12(6) :1665-1671.
  • 7Mitsiades N. A road map to comprehensive androgen re- ceptor axis targeting for castration-resistant prostate cancer [J]. Cancer Res, 2013, 73 (15) :4599-4605.
  • 8Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges [J].Genes Dev, 2010, 24(18) :1967-2000.
  • 9Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate canc- er: Cancer and Leukemia Group B Study 9663 [J]. J Clin Oncol, 2003, 21(14):2673-2678.
  • 10Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-inde- pendent prostate cancer [ J ]. N Engl J IVied, 1995, 332 (21) :1393-1398.

共引文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部